Evidence map›Paper›PMID 36680685›Full record

ArticleCurrent medical science2023

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models.

Fang Huang, Xiao-Bing Jing, Yin-Bo Li, Qian Wang, Si-Li Liu, Zhi-Rong Yang, Su Feng

Open access · bronzeAbstract read
In one paragraph

Article in Current medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Fang HuangKey Laboratory of Biological Resources and Ecological Environment of the Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, 610065, China.
Xiao-Bing JingChengdu Antegen Biotech Co., Ltd., Chengdu, 610041, China.
Yin-Bo LiChengdu Antegen Biotech Co., Ltd., Chengdu, 610041, China.
Qian WangChengdu Antegen Biotech Co., Ltd., Chengdu, 610041, China.
Si-Li LiuChengdu Antegen Biotech Co., Ltd., Chengdu, 610041, China.
Zhi-Rong YangKey Laboratory of Biological Resources and Ecological Environment of the Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, 610065, China.
Su FengKey Laboratory of Biological Resources and Ecological Environment of the Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, 610065, China. fengsu_fs@163.com.
Chengdu Organic Chemicals (China) · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to describe, optimize and evaluate a method for preparing multivalent conjugate vaccines by simultaneous conjugation of two different bacterial capsular polysaccharides (CPs) with tetanus toxoid (TT) as bivalent conjugates.

methodsDifferent molecular weights (MWs) of polysaccharides, activating agents and capsular polysaccharide/protein (CP/Pro) ratio that may influence conjugation and immunogenicity were investigated and optimized to prepare the bivalent conjugate bulk. Using the described method and optimized parameters, a 20-valent pneumococcal conjugate vaccine and a bivalent meningococcal vaccine were developed and their effectiveness was compared to that of corresponding licensed vaccines in rabbit or mouse models.

resultsThe immunogenicity test revealed that polysaccharides with lower MWs were better for Pn1-TT-Pn3 and MenA-TT-MenC, while higher MWs were superior for Pn4-TT-Pn14, Pn6A-TT-Pn6B, Pn7F-TT-Pn23F and Pn8-TT-Pn11A. For activating polysaccharides, 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) was superior to cyanogen bromide (CNBr), but for Pn1, Pn3 and MenC, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDAC) was the most suitable option. For Pn6A-TT-Pn6B and Pn8-TT-Pn11A, rabbits immunized with bivalent conjugates with lower CP/Pro ratios showed significantly stronger CP-specific antibody responses, while for Pn4-TT-Pn14, higher CP/Pro ratio was better. Instead of interfering with the respective immunological activity, our bivalent conjugates usually induced higher IgG titers than their monovalent counterparts.

conclusionThe result indicated that the described conjugation technique was feasible and efficacious to prepare glycoconjugate vaccines, laying a solid foundation for developing extended-valent multivalent or combined conjugate vaccines without potentially decreased immune function.

Indexed as

Neisseria meningitidisAnimalsMiceModels, AnimalPolysaccharides, BacterialRabbitsStreptococcus pneumoniaeTetanus ToxoidVaccines, CombinedVaccines, ConjugatePolysaccharides, BacterialTetanus ToxoidVaccines, CombinedVaccines, Conjugatebioconjugationimmunogenicitymeningococcal conjugate vaccinemultivalent conjugate vaccinepneumococcal conjugate vaccine

Identifiers

PMID36680685
PMCPMC9862236
OpenAlexW4317651625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.